National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedRoth JA, Gulati R, Gore JL
Economic analysis of prostate-specific antigen screening and selective treatment strategies.
The researchers evaluated the potential cost-effectiveness of plausible prostate-specific antigen (PSA) screening strategies and assessed the value added by increased use of conservative management among low-risk, screen-detected cases. They found that, with contemporary treatment, only strategies with biopsy referral for PSA levels higher than 10.0 ng/mL or age-dependent thresholds were associated with increased quality-adjusted life-years (QALYs), and only quadrennial screening of patients aged 55 to 69 years was potentially cost-effective in terms of cost per QALY. They concluded that, for PSA screening to be cost-effective, it needs to be used conservatively and ideally in combination with a conservative management approach for low-risk disease.
AHRQ-funded; HS022982.
Citation: Roth JA, Gulati R, Gore JL .
Economic analysis of prostate-specific antigen screening and selective treatment strategies.
JAMA Oncol 2016 Jul;2(7):890-8. doi: 10.1001/jamaoncol.2015.6275.
.
.
Keywords: Healthcare Costs, Prevention, Cancer: Prostate Cancer, Quality of Life, Screening
Hellinger FJ
AHRQ Author: Hellinger FJ
Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US.
In order to assess the cost-effectiveness of pre-exposure prophylaxis for HIV prevention in the U.S., the author evaluates various studies and finds that they yield widely varying estimates of the cost per quality-adjusted life year (QALY) gained, and that this variations reflects the substantial uncertainty surrounding the determinants of HIV transmission as well as different approaches to translating a reduction in HIV cases into an estimate of the increase in the number of QALYs.
AHRQ-authored.
Citation: Hellinger FJ .
Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US.
Pharmacoeconomics. 2013 Dec;31(12):1091-104. doi: 10.1007/s40273-013-0111-0..
Keywords: Human Immunodeficiency Virus (HIV), Healthcare Costs, Quality of Life, Healthcare Costs, Prevention
Zanocco K, Elaraj D, Sturgeon C
Routine prophylactic central neck dissection for low-risk papillary thyroid cancer: a cost-effectiveness analysis.
The researchers hypothesized that routine prophylactic central neck dissection (pCND) is not cost-effective in low-risk papillary thyroid cancer (PTC).Using a Markov transition-state model, they found that pCND cost $10,315 and produced an effectiveness of 23.785 quality-adjusted life years. They concluded that routine pCND for low-risk PTC is not cost-effective unless the recurrence rate is greater than 10.3 percent.
AHRQ-funded; HS000078.
Citation: Zanocco K, Elaraj D, Sturgeon C .
Routine prophylactic central neck dissection for low-risk papillary thyroid cancer: a cost-effectiveness analysis.
Surgery 2013 Dec;154(6):1148-55; discussion 54-5..
Keywords: Cancer, Surgery, Prevention, Healthcare Costs, Quality of Life